Amicus Therapeutics (NASDAQ:FOLD – Get Rating) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday.
Separately, Morgan Stanley lifted their price objective on shares of Amicus Therapeutics from $14.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Amicus Therapeutics has a consensus rating of “Hold” and a consensus price target of $14.67.
Amicus Therapeutics Price Performance
NASDAQ FOLD opened at $11.91 on Friday. The company has a market cap of $3.35 billion, a PE ratio of -12.95 and a beta of 0.90. The firm’s 50 day moving average price is $11.30 and its 200-day moving average price is $10.93. The company has a debt-to-equity ratio of 2.95, a quick ratio of 2.70 and a current ratio of 2.78. Amicus Therapeutics has a 52-week low of $5.91 and a 52-week high of $12.96.
Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. The business had revenue of $81.69 million for the quarter, compared to the consensus estimate of $84.55 million. Amicus Therapeutics had a negative return on equity of 123.94% and a negative net margin of 81.65%. Sell-side analysts forecast that Amicus Therapeutics will post -0.78 EPS for the current fiscal year.
Insider Activity
In other Amicus Therapeutics news, Chairman John F. Crowley sold 11,346 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $10.75, for a total transaction of $121,969.50. Following the sale, the chairman now owns 845,551 shares of the company’s stock, valued at approximately $9,089,673.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Bradley L. Campbell sold 5,470 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $10.53, for a total value of $57,599.10. Following the completion of the transaction, the chief executive officer now directly owns 689,618 shares in the company, valued at $7,261,677.54. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman John F. Crowley sold 11,346 shares of the company’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $10.75, for a total value of $121,969.50. Following the completion of the sale, the chairman now owns 845,551 shares in the company, valued at approximately $9,089,673.25. The disclosure for this sale can be found here. Insiders have sold a total of 81,868 shares of company stock worth $919,899 over the last 90 days. 2.40% of the stock is currently owned by corporate insiders.
Institutional Trading of Amicus Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of FOLD. JPMorgan Chase & Co. lifted its position in Amicus Therapeutics by 1.4% during the first quarter. JPMorgan Chase & Co. now owns 15,551,816 shares of the biopharmaceutical company’s stock valued at $147,275,000 after purchasing an additional 207,988 shares during the period. US Bancorp DE grew its holdings in Amicus Therapeutics by 16,809.0% during the first quarter. US Bancorp DE now owns 15,049 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 14,960 shares during the period. Oppenheimer Asset Management Inc. raised its position in Amicus Therapeutics by 9.6% during the first quarter. Oppenheimer Asset Management Inc. now owns 60,134 shares of the biopharmaceutical company’s stock valued at $569,000 after acquiring an additional 5,265 shares in the last quarter. Running Point Capital Advisors LLC acquired a new position in Amicus Therapeutics in the first quarter valued at approximately $99,000. Finally, E Fund Management Co. Ltd. grew its stake in shares of Amicus Therapeutics by 71.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 28,875 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12,006 shares during the period.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amicus Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amicus Therapeutics wasn’t on the list.
While Amicus Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
